ABSTRACT
In the United States, causes of racial differences in stroke and its risk factors remain only partly understood, and there is a long-standing disparity in stroke incidence and mortality impacting Black Americans. Only half of the excess risk of stroke in the United States Black population is explained by traditional risk factors, suggesting potential effects of other factors including genetic and biological characteristics. Here, we nonsystematically reviewed candidate laboratory biomarkers for stroke and their relationships to racial disparities in stroke. Current evidence indicates that IL-6 (interleukin-6), a proinflammatory cytokine, mediates racial disparities in stroke through its association with traditional risk factors. Only one reviewed biomarker, Lp(a) (lipoprotein[a]), is a race-specific risk factor for stroke. Lp(a) is highly genetically determined and levels are substantially higher in Black than White people; clinical and pharmaceutical ramifications for stroke prevention remain uncertain. Other studied stroke risk biomarkers did not explain racial differences in stroke. More research on Lp(a) and other biological and genetic risk factors is needed to understand and mitigate racial disparities in stroke.
Subject(s)
Black or African American/genetics , Blood Coagulation/genetics , Health Status Disparities , Inflammation/ethnology , Interleukin-6/genetics , Lipoprotein(a)/genetics , Stroke/ethnology , Biomarkers , Factor VIII/genetics , Factor VIII/metabolism , Fibrin Fibrinogen Degradation Products/genetics , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/genetics , Fibrinogen/metabolism , Genetic Predisposition to Disease , Humans , Incidence , Inflammation/genetics , Protein C/genetics , Protein C/metabolism , Risk Factors , Sickle Cell Trait/ethnology , Sickle Cell Trait/genetics , Stroke/genetics , United StatesABSTRACT
In the present study, we investigated the changes of the coagulation state, bone microthrombus, microvascular bed and bone density levels in iron accumulation rats. Meanwhile,the effect of anticoagulation therapy on bone mineral density was further investigated. We established two groups: a control (Ctrl) group and an iron intervention (FAC) group. Changes in coagulation function, peripheral blood cell counts, bone microthrombus, bone vessels and bone mineral density were compared between the two groups. We designed the non-treatment group and treatment group to study the changes of bone mineral density by preventing microthrombus formation with the anticoagulant fondaparinux. We found that the fibrinogen and D-dimer contents were significantly higher, whereas the thrombin time (TT) and prothrombin time (PT) were significantly shorter in the FAC group. After ink staining, the microvascular bed in the FAC group was significantly reduced compared with that in the Ctrl group. HE and Martius Scarlet Blue (MSB) staining showed microthrombus in the bone marrow of the iron accumulation rats. Following anticoagulation therapy, the bone microcirculation vascular bed areas in the treatment group rats were significantly increased. Furthermore, the bone mineral density was increased in the treatment group compared with that in the non-treatment group. Through experiments, we found that the blood in iron accumulation rat was relatively hypercoagulable; moreover, there was microthrombus in the bone marrow, and the bone vascular bed was reduced. Additionally, anticoagulation was helpful for improving bone microcirculation, reducing microthrombus and decreasing bone loss.
Subject(s)
Bone Resorption/metabolism , Fibrinogen/genetics , Iron/metabolism , Thrombosis/metabolism , Animals , Blood Coagulation/genetics , Bone Density/genetics , Bone Resorption/complications , Bone Resorption/genetics , Bone Resorption/pathology , Disease Models, Animal , Fibrin Fibrinogen Degradation Products/genetics , Fibrinogen/metabolism , Humans , Iron/pharmacology , Rats , Thrombosis/complications , Thrombosis/genetics , Thrombosis/pathologyABSTRACT
The integration of several controlled parameters within a single test system is experiencing increased demand. However, multiplexed test systems typically require complex manufacturing. Here, we describe a multiplexed immunochromatographic assay that incorporates a conventional nitrocellulose membrane, which is used together with microspot printing, to construct adjacent microfluidic "tracks" for multiplexed detection. The 1 mm distance between tracks allows for the detection of up to four different analytes. The following reagents are applied in separate zones: (a) gold nanoparticle conjugates with antibodies against each analyte, (b) other antibodies against each analyte, and (c) antispecies antibodies. The immersion of the test strip in the sample initiates the lateral flow, during which reagents of different specificities move along their tracks without track erosion or reagent mixing. An essential advantage of the proposed assay is its extreme rapidity (1-1.5 min compared with 10 min for common test strips). This assay format was applied to the detection of cardiac and inflammatory markers (myoglobin, D-dimer, and C-reactive protein) in human blood, and was characterized by high reproducibility (8%-15% coefficient of variation) with stored working ranges of conventional tests. The universal character of the proposed approach will facilitate its use for various analytes.
Subject(s)
Antibodies/isolation & purification , Biosensing Techniques , Diagnostic Techniques, Cardiovascular , Immunoassay/methods , Antibodies/genetics , C-Reactive Protein/genetics , C-Reactive Protein/isolation & purification , Chromatography, Affinity , Fibrin Fibrinogen Degradation Products/genetics , Fibrin Fibrinogen Degradation Products/isolation & purification , Gold/chemistry , Humans , Metal Nanoparticles/chemistry , Myoglobin/blood , Myoglobin/isolation & purification , Reagent Strips/chemistryABSTRACT
Persons with HIV infection (PWH) have increased risk for cardiovascular disease (CVD), but the underlying mechanisms remain unclear. Coronary thrombosis is known to provoke myocardial infarctions, but whether PWH have elevated thrombotic propensity is unknown. We compared thrombogenicity of PWH on antiretroviral therapy versus matched controls using the Badimon chamber. Measures of inflammation, platelet reactivity, and innate immune activation were simultaneously performed. Enrolled PWH were then randomized to placebo, aspirin (81 mg), or clopidogrel (75 mg) for 24 weeks to assess treatment effects on study parameters. Thrombogenicity was significantly higher in PWH and correlated strongly with plasma levels of D-dimer, soluble TNF receptors 1 and 2, and circulating classical and nonclassical monocytes in PWH. Clopidogrel significantly reduced thrombogenicity and sCD14. Our data suggest that higher thrombogenicity, interacting with inflammatory and immune activation markers, contributes to the increased CVD risk observed in PWH. Clopidogrel exhibits an anti-inflammatory activity in addition to its antithrombotic effect in PWH.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Aspirin/therapeutic use , Blood Platelets/drug effects , Clopidogrel/therapeutic use , Coronary Thrombosis/drug therapy , HIV Infections/drug therapy , Platelet Aggregation Inhibitors/therapeutic use , Adult , Antiretroviral Therapy, Highly Active/methods , Biomarkers/blood , Blood Platelets/immunology , Blood Platelets/virology , Coronary Thrombosis/complications , Coronary Thrombosis/immunology , Coronary Thrombosis/virology , Cross-Sectional Studies , Female , Fibrin Fibrinogen Degradation Products/genetics , Fibrin Fibrinogen Degradation Products/immunology , Gene Expression , HIV Infections/complications , HIV Infections/immunology , HIV Infections/virology , Humans , Immunity, Innate , Inflammation , Lipopolysaccharide Receptors/genetics , Lipopolysaccharide Receptors/immunology , Male , Middle Aged , Monocytes/drug effects , Monocytes/immunology , Monocytes/virology , Platelet Aggregation/drug effects , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type I/immunology , Receptors, Tumor Necrosis Factor, Type II/genetics , Receptors, Tumor Necrosis Factor, Type II/immunologySubject(s)
Afibrinogenemia/genetics , Fibrin Fibrinogen Degradation Products/genetics , Fibrin/genetics , Point Mutation , Adolescent , Afibrinogenemia/blood , Afibrinogenemia/complications , Afibrinogenemia/metabolism , Blood Coagulation , Female , Fibrin/metabolism , Fibrin Fibrinogen Degradation Products/metabolism , Humans , Male , Pedigree , Thrombosis/blood , Thrombosis/complications , Thrombosis/genetics , Thrombosis/metabolismABSTRACT
The identification of rare coding or splice site variants remains the most straightforward strategy to link genes with human phenotypes. Here, we analyzed the association between 137,086 rare (minor allele frequency (MAF) <1%) coding or splice site variants and 15 hematological traits in up to 308,572 participants. We found 56 such rare coding or splice site variants at P<5x10-8, including 31 that are associated with a blood-cell phenotype for the first time. All but one of these 31 new independent variants map to loci previously implicated in hematopoiesis by genome-wide association studies (GWAS). This includes a rare splice acceptor variant (rs146597587, MAF = 0.5%) in interleukin 33 (IL33) associated with reduced eosinophil count (P = 2.4x10-23), and lower risk of asthma (P = 2.6x10-7, odds ratio [95% confidence interval] = 0.56 [0.45-0.70]) and allergic rhinitis (P = 4.2x10-4, odds ratio = 0.55 [0.39-0.76]). The single new locus identified in our study is defined by a rare p.Arg172Gly missense variant (rs145535174, MAF = 0.05%) in plasminogen (PLG) associated with increased platelet count (P = 6.8x10-9), and decreased D-dimer concentration (P = 0.018) and platelet reactivity (P<0.03). Finally, our results indicate that searching for rare coding or splice site variants in very large sample sizes can help prioritize causal genes at many GWAS loci associated with complex human diseases and traits.
Subject(s)
Asthma/blood , Endometriosis/blood , Genome, Human , Polymorphism, Single Nucleotide , Rhinitis, Allergic/blood , Asthma/genetics , Databases, Genetic , Endometriosis/genetics , Female , Fibrin Fibrinogen Degradation Products/genetics , Fibrin Fibrinogen Degradation Products/metabolism , Gene Frequency , Genetic Loci , Genome-Wide Association Study , Humans , Interleukin-33/genetics , Interleukin-33/metabolism , Linear Models , Logistic Models , Male , Mutation, Missense , Phenotype , Plasminogen/genetics , Plasminogen/metabolism , Platelet Count , Principal Component Analysis , Protein Splicing/genetics , Rhinitis, Allergic/genetics , Sequence Analysis, DNAABSTRACT
Patients with overgrowth and complex vascular malformation syndromes, including Proteus syndrome have an increased risk of thromboembolism. Proteus syndrome is a mosaic, progressive overgrowth disorder involving vasculature, skin, and skeleton, and caused by a somatic activating mutation in AKT1. We conducted a comprehensive review of the medical histories and hematologic evaluations of 57 patients with Proteus syndrome to identify potential risk factors for thrombosis. We found that six of ten patients, who were deceased, died secondary to deep venous thrombosis and/or pulmonary embolism. Of the remaining 47 living patients, six had thromboembolic events that all occurred postoperatively and in an affected limb. Eleven of 21 patients had an abnormal hypercoagulable panel including Factor V Leiden heterozygotes, antithrombin III deficiency, positive lupus anticoagulant, or Protein C or S deficiencies. We observed that eight of 17 patients had an abnormal D-dimer level >0.5 mcg/dl, but deep venous thromboses occurred in only four of those with D-dimer >1.0 mcg/dl. We conclude that the predisposition to thrombosis is likely to be multifaceted with risk factors including vascular malformations, immobility, surgery, additional prothrombotic factors, and possible pathophysiologic effects of the somatic AKT1 mutation on platelet function or the vascular endothelium. The D-dimer test is useful as a screen for thromboembolism, although the screening threshold may need to be adjusted for patients with this disorder. We propose developing a registry to collect D-dimer and outcome data to facilitate adjustment of the D-dimer threshold for Proteus syndrome and related disorders, including PIK3CA-Related Overgrowth Spectrum.
Subject(s)
Fibrin Fibrinogen Degradation Products/genetics , Proteus Syndrome/genetics , Proto-Oncogene Proteins c-akt/genetics , Pulmonary Embolism/genetics , Thrombosis/genetics , Adolescent , Adult , Aged , Antithrombin III Deficiency/blood , Antithrombin III Deficiency/genetics , Child , Child, Preschool , Endothelium, Vascular/metabolism , Endothelium, Vascular/pathology , Factor V/genetics , Female , Humans , Lupus Coagulation Inhibitor/blood , Male , Middle Aged , Protein C Deficiency/blood , Protein S Deficiency/blood , Proteus Syndrome/blood , Proteus Syndrome/physiopathology , Proto-Oncogene Proteins c-akt/blood , Pulmonary Embolism/blood , Pulmonary Embolism/physiopathology , Risk Factors , Thrombosis/blood , Thrombosis/physiopathologyABSTRACT
An association between blood markers of thrombosis and haemostasis and cognitive decline has been described. These results may be confounded by lifestyle and environmental factors. We used a Mendelian randomisation approach to describe the association between thrombosis/haemostasis genotypes and cognition. We studied the genetic variants (single nucleotide polymorphisms) of circulating markers of thrombosis and haemostasis. Our chosen blood factors and associated polymorphisms were D-dimer [rs12029080], fibrinogen [rs1800789], plasminogen activator inhibitor [rs2227631], and von Willebrand factor [rs1063857]. We described association with multidomain cognitive test scores using data from the Scottish Family Health Study. Cognitive data were analysed for individual tests and combined to give a general cognitive factor. In 20,288 subjects, we found no evidence of association between cognitive function (individual tests and combined scores) and any of the above-mentioned single nucleotide polymorphisms. Lower scores on cognitive measures were associated with increasing age, socioeconomic deprivation, blood pressure, waist-hip ratio, smoking, and vascular comorbidity (all p < 0.001). In a post hoc sensitivity analysis restricted to those aged over 50 years, there was still no signal of association. Our data add to our understanding of determinants of cognition but are not definitive; the variation in blood levels explained by SNPs was modest and our sample size may have been insufficient to detect a modest association.
Subject(s)
Cognition Disorders/genetics , Fibrin Fibrinogen Degradation Products/genetics , Plasminogen Activator Inhibitor 1/genetics , Polymorphism, Single Nucleotide/genetics , Thrombosis/genetics , von Willebrand Factor/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Hemostasis/genetics , Humans , Independent Living , Male , Mendelian Randomization Analysis , Middle Aged , Scotland , Thrombosis/psychology , Young AdultABSTRACT
Fibrin deposition and remodelling of the extracellular matrix are important early steps in tumour metastasis. The D-dimer value is an indicator of intravascular fibrin formation and degradation. Thus, the D-dimer value may be a predictor of the malignant involvement of lymph nodes in operable non-small cell lung cancer (NSCLC) patients. The study comprised 142 highly suspected lung cancer patients scheduled to undergo pneumonectomy, lobectomy or wedge resection. Of the 142 patients, 124 were subsequently diagnosed as NSCLC, and 18 were subsequently diagnosed as benign lung disease by histological examination. Preoperative plasma D-dimer values were quantified, and the relationship between plasma D-dimer and clinical variables including tumour size, involvement of lymph nodes and clinical stage was examined using Spearman correlation coefficients and χ (2) tests. The median plasma D-dimer values were statistically higher in NSCLC patients with malignant lymph nodes than in those who suffered either benign lung disease or carcinoma in situ (Kruskal-Wallis test; P = 0.001). Plasma D-dimer values were significantly correlated with clinical stage (ANOVA; P = 0.009). An obvious relationship was observed between elevated D-dimer (>0.475 mg/L fibrinogen equivalent units) and malignant lymph node involvement (χ (2) test; P = 0.0000). This correlation suggests that the plasma D-dimer value is a clinically important predictor for the malignant involvement of lymph nodes in operable NSCLC.
Subject(s)
Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/genetics , Fibrin Fibrinogen Degradation Products/genetics , Prognosis , Adult , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Female , Fibrin Fibrinogen Degradation Products/metabolism , Humans , Lymph Nodes/metabolism , Lymph Nodes/pathology , Lymphatic Metastasis/genetics , Lymphatic Metastasis/pathology , Male , Middle Aged , Neoplasm StagingABSTRACT
OBJECTIVE: The aim of this study was to identify biomarkers with prognostic value in the setting of surgically treated endometrial cancer. METHODS: Medical data for 282 patients with surgically treated endometrial cancer were reviewed retrospectively. Preoperative concentrations of six serum biomarkers (CA125, CA15-3, C-reactive protein [CRP], D-dimer [D-D], platelet-to-lymphocyte ratio [PLR], and neutrophil-to-lymphocyte ratio [NLR]) were analysed to determine potential associations with clinicopathologic characteristics and to assess prognostic values separately via Kaplan-Meier method and multivariate Cox regression. RESULTS: In univariate analyses, the 5-year overall survival (OS) rate was 86.5% for a maximum follow-up period of 75 months. High concentrations of CA125, CA15-3, CRP, D-D, PLR, and NLR each proved significantly predictive of poor survival (log-rank test, P<0.01). CRP and D-D were identified as independent prognosticators, using a Cox regression model. Study patients were then stratified (based on combined independent risk factors) into three tiers (P<0.001), marked by 5-year OS rates of 92.1%, 78.4%, and 33.3%. CONCLUSIONS: All serum biomarkers assessed (CA125, CA15-3, CRP, D-D, PLR, and NLR) proved to be valid prognostic indices of surgically treated endometrial cancer. A novel prognostic grouping system, incorporating independent risk factors (CRP and D-D Concentrations), may have merit in assessing these patients preoperatively, providing a biologic basis for improved clinical staging.
Subject(s)
Biomarkers, Tumor/genetics , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/surgery , Adult , Aged , Biomarkers, Tumor/blood , Blood Platelets/pathology , C-Reactive Protein/genetics , C-Reactive Protein/metabolism , CA-125 Antigen/blood , CA-125 Antigen/genetics , Endometrial Neoplasms/genetics , Endometrial Neoplasms/mortality , Female , Fibrin Fibrinogen Degradation Products/genetics , Fibrin Fibrinogen Degradation Products/metabolism , Humans , Lymphocytes/pathology , Membrane Proteins/blood , Membrane Proteins/genetics , Middle Aged , Mucin-1/blood , Mucin-1/genetics , Multivariate Analysis , Neutrophils/pathology , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Factors , Survival RateABSTRACT
In human gliomas, tissue factor (TF) is overexpressed, associated with the grade of malignancy and influences tumour biology. Intra-tumoural fibrin/fibrinogen deposition and activation of the fibrinolytic system also play a role in tumour cell proliferation and angiogenesis. The first aim of the present study was to investigate TF expression and the presence of fibrin/fibrinogen and D-dimers in canine glioma biopsies, graded according to the World Health Organization (WHO) classification of tumours of the central nervous system. The second aim was to investigate the occurrence of intravascular thrombosis (IVT) in canine gliomas, as a potential histological marker of glioma type or grade of malignancy. An immunohistochemical study using antibodies against TF, fibrin/fibrinogen and D-dimers was performed with 24 glioma samples, including 15 oligodendrogliomas, 6 astrocytomas and 3 mixed gliomas. Immunohistochemical data were statistically analysed to determine whether there was any relationship between glioma type and grade of malignancy. All gliomas were moderate to strongly positive for TF and the staining score was significantly higher (P = 0.04) in high-grade (III or IV) than in low-grade (II) gliomas. Intra-tumoural fibrin/fibrinogen deposition was detected in all tumour biopsies assessed, and D-dimers were detected in 17/24 gliomas. IVT was a frequent finding, but was not linked to a specific glioma type or malignancy grade. TF expression, fibrin/fibrinogen deposition, extravascular fibrinolytic system activation and IVT occur in canine gliomas. Canine glioma might be a suitable model for studying coagulation and fibrinolysis as potential therapeutic targets for human gliomas.
Subject(s)
Dog Diseases/metabolism , Fibrin/genetics , Fibrinogen/genetics , Gene Expression , Glioma/veterinary , Thromboplastin/genetics , Thrombosis/veterinary , Animals , Astrocytoma/etiology , Astrocytoma/metabolism , Astrocytoma/veterinary , Biomarkers , Dog Diseases/etiology , Dogs , Fibrin/metabolism , Fibrin Fibrinogen Degradation Products/genetics , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Glioma/etiology , Glioma/metabolism , Immunohistochemistry/veterinary , Oligodendroglioma/etiology , Oligodendroglioma/metabolism , Oligodendroglioma/veterinary , Spain , Thromboplastin/metabolism , Thrombosis/etiology , Thrombosis/metabolismABSTRACT
INTRODUCTION: A low D-dimer is commonly used to exclude venous thromboembolism in low risk patients. However, the reference intervals are poorly defined and D-dimer has been shown to increase by patient age. We aimed to establish age- and sex-dependent D-dimer reference intervals and to test the consequence of different cut-off limits. MATERIALS AND METHODS: By means of the STA-Lia test D-dimer was measured in 1,352 subjects aged between 23 and 93years from the general population. A further 94 subjects were measured with the HemosIL test. RESULTS: The reference intervals were age-dependent with the upper 95% limit increasing from 0.92 FEU mg/L in the age group <50years to 2.39 FEU mg/L in the group ≥70years. Minor differences in the reference intervals between sexes were found. The commonly used cut-off at 0.5 FEU mg/L resulted in a decrease of negatives from 91% in <50years to 56 % in ≥70years. The age-dependent cut-off value (patient's age*0.01 FEU mg/L in 50+ years) resulted in an increase of negatives by age. The linear increase in D-dimer has a slope at approximately 0.0077*age, meaning that a cut-off at (patient's age*0.0077) FEU mg/L, gives an almost constant number of positives across age groups. The two assays showed a poor correlation and a higher percentage of positives using the STA Lia test. CONCLUSIONS: The age-dependent increase in D-dimer seen in patients was confirmed, which questions the clinical value of the present cut-off for venous thromboembolism.
Subject(s)
Fibrin Fibrinogen Degradation Products/metabolism , Adult , Age Factors , Aged , Aged, 80 and over , Fibrin Fibrinogen Degradation Products/genetics , Humans , Middle Aged , Reference Values , Sex Factors , Young AdultABSTRACT
INTRODUCTION: Postoperative adhesions after abdominal or pelvic surgery remain an important clinical problem causing infertility, pain and bowel obstruction. Their prevention and treatment remains poorly understood and inadequate. The formation of adhesions is caused by the organization of a fibrin matrix, an organization that takes place during the coagulation process when there is suppression of fibrinolysis. METHODS: In this study peritoneal tissue and peritoneal fluid from two groups of patients were sampled and analysed. The first group comprised of 12 patients undergoing abdominal surgery for an acute abdomen during which known peritoneal factors of aggression (trauma, chemical, bacterial) were present which are known to increase the propensity for peritoneal adhesion formation. A second group consisting of 6 patients undergoing surgery in the absence of these peritoneal aggression factors acted as a reference control group. Each patient had peritoneal tissue sampled at the time of surgery and analysed for levels of gene expression of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1). Patients also had peritoneal drain fluid collected postoperatively and analysed for quantities of fibrin degradation products (FDPs) and fibrinogen. RESULTS: The aim of this study was to evaluate the role of PAI-1 and tPA genes at peritoneal tissue level. Peritoneal tissue was obtained during surgery and the variation of expression of PAI-1 and tPA genes was quantified. The obtained results highlighted an increase of expression in PAI-1 gene and decrease of expression in tPA gene in patients with increased factors of peritoneal aggression compared to patients without, indicating a decreased fibrinolytic potential in patients with increased peritoneal adhesion propensity. Increased factors of peritoneal aggression also resulted in increased levels of FDPs and fibrinogen in peritoneal exudates.
Subject(s)
Ascitic Fluid/metabolism , Fibrinolysis/genetics , Peritoneum/metabolism , Peritoneum/surgery , Plasminogen Activator Inhibitor 1/genetics , Tissue Plasminogen Activator/genetics , Abdomen, Acute/surgery , Anticoagulants/metabolism , Biomarkers/metabolism , Biopsy , Case-Control Studies , Fibrin Fibrinogen Degradation Products/genetics , Fibrinolytic Agents/metabolism , Humans , Peritoneum/pathology , Tissue Adhesions/metabolism , Tissue Adhesions/surgeryABSTRACT
INTRODUCTION: Fibrinogen is a key component of the blood coagulation system and plays important, diverse roles in several relevant pathologies such as thrombosis, hemorrhage, and cancer. It is a large glycoprotein whose three-dimensional molecular structure is not fully known. Furthermore, circulating fibrinogen is highly heterogeneous, mainly due to proteolytic degradation and alternative mRNA processing. Recombinant production of human fibrinogen allows investigating the impact on the three-dimensional structure of specific changes in the primary structure. METHODS: We performed analytical ultracentrifugation analyses of a full-length recombinant human fibrinogen, its counterpart purified from human plasma, and a recombinant human fibrinogen with both Aα chains truncated at amino acid 251, thus missing their last 359 amino acid residues. RESULTS: We have accurately determined the translational diffusion and sedimentation coefficients (Dt(20,w)(0), s(20,w)(0)) of all three species. This was confirmed by derived molecular weights within 1% for the full length species, and 5% for the truncated species, as assessed by comparison with SDS-PAGE/Western blot analyses and primary structure data. No significant differences in the values of Dt(20,w)(0) and s(20,w)(0) were found between the recombinant and purified full length human fibrinogens, while slightly lower and higher values, respectively, resulted for the recombinant truncated human fibrinogen compared to a previously characterized purified human fibrinogen fragment X obtained by plasmin digestion. CONCLUSIONS: Full-length recombinant fibrinogen is less polydisperse but hydrodynamically indistinguishable from its counterpart purified from human plasma. Recombinant Aα251-truncated human fibrinogen instead behaves differently from fragment X, suggesting a role for the Bß residues 1-52 in inter-molecular interactions. Overall, these new hydrodynamic data will constitute a reliable benchmark against which models of fibrinogen species could be compared.
Subject(s)
Fibrinogen/chemistry , Blotting, Western , Chromatography, Reverse-Phase , Electrophoresis, Polyacrylamide Gel , Fibrin Fibrinogen Degradation Products/chemistry , Fibrin Fibrinogen Degradation Products/genetics , Fibrinogen/genetics , Fibrinogen/isolation & purification , Humans , Hydrodynamics , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , UltracentrifugationABSTRACT
A number of single nucleotide polymorphisms (SNP) have been linked to higher risk of venous thromboembolism (VTE). We investigated the VTE risk associated with SNPs in the GP6 (rs1613662), SERPINC1 (rs2227589), F11 (rs2036914 and rs2289252), FGG (rs2066865), and F12 (rs1801020) genes. In F11, the CC genotype for rs2036914 and the CT and TT genotypes for rs2289252 were associated with a significantly higher VTE risk. A trend toward a thrombogenic effect was observed for the risk alleles of the GP6 and FGG SNPs. Risk estimates were unaffected by adjustments for blood type and F5 rs6025 (Factor V Leiden) mutation.
Subject(s)
Venous Thrombosis/genetics , Antithrombin III/genetics , Cell Adhesion Molecules/genetics , Cohort Studies , Denmark , Factor XII/genetics , Fibrin Fibrinogen Degradation Products/genetics , Genetic Predisposition to Disease , Humans , Platelet Membrane Glycoproteins/genetics , Polymorphism, Single Nucleotide , Receptors, Cell Surface/genetics , Risk Factors , Venous Thrombosis/bloodABSTRACT
Fibrin polymerization occurs in two steps: the assembly of fibrin monomers into protofibrils and the lateral aggregation of protofibrils into fibers. Here we describe a novel fibrinogen that apparently impairs only lateral aggregation. This variant is a hybrid, where the human αC region has been replaced with the homologous chicken region. Several experiments indicate this hybrid human-chicken (HC) fibrinogen has an overall structure similar to normal. Thrombin-catalyzed fibrinopeptide release from HC fibrinogen was normal. Plasmin digests of HC fibrinogen produced fragments that were similar to normal D and E; further, as with normal fibrinogen, the knob 'A' peptide, GPRP, reversed the plasmin cleavage associated with addition of EDTA. Dynamic light scattering and turbidity studies with HC fibrinogen showed polymerization was not normal. Whereas early small increases in hydrodynamic radius and absorbance paralleled the increases seen during the assembly of normal protofibrils, HC fibrinogen showed no dramatic increase in scattering as observed with normal lateral aggregation. To determine whether HC and normal fibrinogen could form a copolymer, we examined mixtures of these. Polymerization of normal fibrinogen was markedly changed by HC fibrinogen, as expected for mixed polymers. When the mixture contained 0.45 µM normal and 0.15 µM HC fibrinogen, the initiation of lateral aggregation was delayed and the final fiber size was reduced relative to normal fibrinogen at 0.45 µM. Considered altogether, our data suggest that HC fibrin monomers can assemble into protofibrils or protofibril-like structures, but these either cannot assemble into fibers or assemble into very thin fibers.
Subject(s)
Fibrin Fibrinogen Degradation Products/chemical synthesis , Fibrin Fibrinogen Degradation Products/genetics , Fibrinogen/chemistry , Fibrinogen/genetics , Mutant Chimeric Proteins/chemistry , Mutant Chimeric Proteins/genetics , Peptide Fragments/chemistry , Peptide Fragments/genetics , Amino Acid Substitution/genetics , Animals , CHO Cells , Chickens , Cricetinae , Cricetulus , Fibrinogen/metabolism , Humans , Mutant Chimeric Proteins/metabolism , Peptide Fragments/metabolism , Protein Multimerization/genetics , Protein Stability , Protein Structure, Secondary/genetics , Protein Structure, Tertiary/genetics , Structural Homology, ProteinABSTRACT
BACKGROUND: Fibrin fragment D-dimer, one of several peptides produced when crosslinked fibrin is degraded by plasmin, is the most widely used clinical marker of activated blood coagulation. To identity genetic loci influencing D-dimer levels, we performed the first large-scale, genome-wide association search. METHODS AND RESULTS: A genome-wide investigation of the genomic correlates of plasma D-dimer levels was conducted among 21 052 European-ancestry adults. Plasma levels of D-dimer were measured independently in each of 13 cohorts. Each study analyzed the association between ≈2.6 million genotyped and imputed variants across the 22 autosomal chromosomes and natural-logtransformed D-dimer levels using linear regression in additive genetic models adjusted for age and sex. Among all variants, 74 exceeded the genome-wide significance threshold and marked 3 regions. At 1p22, rs12029080 (P=6.4×10(-52)) was 46.0 kb upstream from F3, coagulation factor III (tissue factor). At 1q24, rs6687813 (P=2.4×10(-14)) was 79.7 kb downstream of F5, coagulation factor V. At 4q32, rs13109457 (P=2.9×10(-18)) was located between 2 fibrinogen genes: 10.4 kb downstream from FGG and 3.0 kb upstream from FGA. Variants were associated with a 0.099-, 0.096-, and 0.061-unit difference, respectively, in natural-logtransformed D-dimer and together accounted for 1.8% of the total variance. When adjusted for nonsynonymous substitutions in F5 and FGA loci known to be associated with D-dimer levels, there was no evidence of an additional association at either locus. CONCLUSIONS: Three genes were associated with fibrin D-dimer levels. Of these 3, the F3 association was the strongest, and has not been previously reported.
Subject(s)
Blood Coagulation/genetics , Factor V/genetics , Fibrin Fibrinogen Degradation Products/genetics , Genome-Wide Association Study , Thromboplastin/genetics , Adult , Aged , Female , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/genetics , Genetic Testing , Humans , Male , Middle Aged , Reference Values , White People/genetics , White People/statistics & numerical dataABSTRACT
The role of ethanol metabolism in possible haemostatic cardioprotective effects has not yet been determined. To this end, we investigated the effect of a moderate dose of ethanol (35 g) and its metabolism, on haemostatic variables over 14 hours (h). Eighteen Caucasian males participated in a placebo-controlled, randomised, cross-over study. Blood was collected prior to alcohol consumption, and at 10 time points for 14 h. Blood ethanol peaked at 1 h and was cleared after 8 h following ethanol consumption, significantly increasing plasma acetate (p=0.0028). Ethanol did not influence the coagulation factors significantly. PAI-1act increased (p<0.0001) and tPAact (p=0.047) decreased following alcohol consumption, reaching maximum (0.69 to 22.2 IU/ml) and minimum (0.88 to 0.33 IU/ml) levels at 5 h, respectively. Significantly increased plasma clot lysis times (46.8 to 67.6 minutes) and reduced global fibrinolytic capacity of whole blood, measured as D-dimer production during incubation of blood clots (2.26 to 0.29 µg/ml), were found at 5 h. Except for PAI-1act (borderline significance; p=0.05), there was no significant difference in the fibrinolytic markers between the two groups the following morning. Moderate ethanol consumption resulted in a significant temporary fibrinolysis inhibition. Any protective effects of moderate ethanol consumption on cardiovascular disease do not appear to be due to improvement in fibrinolytic potential within the first 14 h following consumption. The use of global fibrinolytic assays is recommended for determining the true effect of ethanol on fibrinolysis.
Subject(s)
Blood Cells/metabolism , Ethanol/administration & dosage , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinolysis/drug effects , Plasminogen Activator Inhibitor 1/metabolism , Acetates/blood , Adult , Biomarkers/metabolism , Blood Cells/drug effects , Blood Cells/pathology , Blood Coagulation Factors/metabolism , Cells, Cultured , Fibrin Fibrinogen Degradation Products/genetics , Humans , Male , Plasminogen Activator Inhibitor 1/geneticsABSTRACT
BACKGROUND AND AIMS: D-dimer is a marker of active fibrinolysis. Understanding how age-related factors affect D-dimer levels may help the interpretation of high D-dimer levels in older individuals. METHODS: 776 Baltimore Longitudinal Study on Aging (BLSA) participants (mean age 68.4+/-13.9 yrs) were divided into three groups according to baseline D-dimer levels >200 ng/mL; 100-200 ng/mL and <100 ng/mL. RESULTS: D-dimer level increased with age (p<0.0001). Using polychotomous logistic regression models, we found that age, cholesterol, triglycerides, creatinine, erythrocyte sedimentation rate, hemoglobin and body mass index were independently associated with D-dimer level. CONCLUSIONS: Rising levels of D-dimer with age can be explained in part by the high prevalence of pro-inflammatory conditions and increasing burden of lipid abnormalities, anemia and obesity. These factors compromise the specificity of D-dimer levels as a diagnostic aid to thrombosis in older individuals.